Provider of personalized molecular services designed to detect genomic and proteomic alterations in cancer. The company's molecular diagnostics approach combines DNA sequencing, RNA sequencing and quantitative proteomics to unearth the genomic and proteomic variances that initiate and drive cancer, by analysing both normal and tumour cells, enabling cancer patients to access personalized point of care.